Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal

Hormone and Metabolic Research

Volumn 40, Issue 8, 2008, Pages 544-548

  Rosak, C ^a   Jung, R ^a   Hofmann, U ^a  

^a Carl von Noorden Klinikum Sachsenhausen   (Germany)

Author keywords

Basal insulin; Blood glucose; Flexibility; Insulin analogue

Indexed keywords

3 HYDROXYBUTYRIC ACID; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETIC FOOT; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MEAL; METABOLIC REGULATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

3-HYDROXYBUTYRIC ACID; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EATING; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; LIPID METABOLISM; MALE;

EID: 50249170464     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1065328     Document Type: Article

References (11)

1. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23:1130-1136
2. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649
3. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartoca L, Vincenzo A Di, Cordoni C, Costa E, Brunetti P, Bolli CB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148
4. Owens D, Coates P, Luzio S, Tinbergen J, Kurzhals R. Pharmacokinetics of [125]1-labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000; 23: 813-819
5. Massi Benedetti M, Hamburg E, Dressier A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196
6. Riddle M, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
7. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005; 48: 1988-1995
8. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26: 1490-1496
9. Hamann A, Matthaei S, Rosak C, Silvestre L. HOE901 /4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-1744
10. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004; 66: 49-56
11. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002; 18: S64-S69